Atjaunināt sīkdatņu piekrišanu

Internal Medicine Evidence [Mīkstie vāki]

5.00/5 (2 ratings by Goodreads)
,
  • Formāts: Paperback / softback, 240 pages, height x width: 229x152 mm, weight: 340 g
  • Izdošanas datums: 02-May-2017
  • Izdevniecība: Lippincott Williams and Wilkins
  • ISBN-10: 1496343557
  • ISBN-13: 9781496343550
Citas grāmatas par šo tēmu:
  • Mīkstie vāki
  • Cena: 61,07 €*
  • * Šī grāmata vairs netiek publicēta. Jums tiks paziņota lietotas grāmatas cena
  • Šī grāmata vairs netiek publicēta. Jums tiks paziņota lietotas grāmatas cena.
  • Daudzums:
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
Internal Medicine EvidencePalielināt
  • Formāts: Paperback / softback, 240 pages, height x width: 229x152 mm, weight: 340 g
  • Izdošanas datums: 02-May-2017
  • Izdevniecība: Lippincott Williams and Wilkins
  • ISBN-10: 1496343557
  • ISBN-13: 9781496343550
Citas grāmatas par šo tēmu:
Permanent link: https://www.kriso.lv/db/9781496343550.html
Keywords:
Increase your knowledge of the clinical trials and evidence that lay the groundwork for current practice with Internal Medicine Evidence: The Practice-Changing Studies. Brief, easy-to-read, accessible, and reviewed by experienced clinicians at Harvard Medical School, this time-saving reference allows you to quickly familiarize yourself with 100 of the most practice-changing clinical trials in internal medicine. This unique title is ideal for trainees and seasoned practitioners in medicine, nursing and other health professions, providing insight and understanding into today’s practice of internal medicine.

Key Features:
  • Save time and effort with convenient, succinct synopses of each study, including editorial commentary on the impact of the trial and the context for incorporating it into practice.
  • Access an important mix of historical and contemporary studies, reviewed by faculty at Harvard Medical School, with an emphasis on material most relevant to today’s practice.
  • Explore landmark clinical trials in all areas of internal medicine, including cardiology, critical care, endocrinology, gastroenterology, hematology, infectious diseases, nephrology, oncology, pulmonology, and rheumatology.
Your book purchase includes a complimentary download of the enhanced eBook for iOS, Android, PC & Mac. Take advantage of these practical features that will improve your eBook experience:
  • The ability to download the eBook on multiple devices at one time — providing a seamless reading experience online or offline
  • Powerful search tools and smart navigation cross-links that allow you to search within this book, or across your entire library of VitalSource eBooks
  • Multiple viewing options that enable you to scale images and text to any size without losing page clarity as well as responsive design
  • The ability to highlight text and add notes with one click


Increase your knowledge of the clinical trials and evidence that lay the groundwork for current practice with Internal Medicine Evidence: The Practice-Changing Studies. Brief, easy-to-read, and accessible, this time-saving reference allows you to quickly familiarize yourself with 100 of the most practice-changing clinical trials in internal medicine. This unique title is ideal for medical students, residents, and seasoned practitioners alike, providing insight and understanding into today’s practice of internal medicine.

Recenzijas

"collection of past evidence-based journal articles that have stood the test of time" "appeals to specialists whose practice encompasses these articles and those who wish to review the historical context of medicine" "Each chapter gives a short background of the issue, the objectives of the study, the key results, conclusions, and a commentary." Doody's Star Rating ®: 2 stars Score: 58 -Doodys Publishers' Club, Friday, July 7, 2017

SECTION 1 CARDIOLOGY
Joshua M. Liao
1 Rate Versus Rhythm Control in Atrial Fibrillation: The AFFIRM Trial
2(2)
2 Angioplasty Versus Streptokinase in Myocardial Infarction
4(2)
3 First-Step Antihypertensive Therapy: The ALLHAT Trial
6(2)
4 Heart Failure Treatment for African Americans: The A-HeFT Trial
8(2)
5 Dual Antiplatelet Therapy in Non--ST-Elevation ACS: The CURE Trial
10(2)
6 ACE Inhibitors in Congestive Heart Failure: The CONSENSUS Trial
12(2)
7 CRT in Advanced Heart Failure: The COMPANION Trial
14(2)
8 Beta Blockers in Chronic Heart Failure: The COMET Trial
16(2)
9 Antiplatelet Therapy for Preventing Vascular Events
18(2)
10 Statin Therapy After ACS: PROVE IT-TIMI 22
20(2)
11 Transcatheter Aortic Valve Implantation: The PARTNER B Trial
22(2)
12 Angioplasty Versus t-PA in Myocardial Infarction: The PAMI-1 Study
24(2)
13 Aspirin and Thrombolysis in Myocardial Infarction: The ISIS-2 Trial
26(2)
14 Heparin in ACS without ST Elevation
28(2)
15 PCI Versus CABG for Severe CAD: The SYNTAX Trial
30(2)
16 Antiarrhythmics and ICDs in CHF: The SCD-HeFT Trial
32(2)
17 ACE Inhibitors in LV Dysfunction: The SAVE Trial
34(2)
18 Dabigatran for Atrial Fibrillation: The RE-LY Trial
36(2)
19 Spironolactone in Severe HF: The RALES Trial
38(2)
20 Cholesterol Lowering in Coronary Artery Disease: The 4S Trial
40(4)
SECTION 2 CRITICAL CARE
Zahir Kanjee
21 Glucose Control in ICU Patients: The NICE-SUGAR Trial
44(2)
22 Therapeutic Hypothermia after Cardiac Arrest: The HACA Trial
46(2)
23 Corticosteroids in Septic Shock: The CORTICUS Trial
48(2)
24 Low Tidal Volume Ventilation for Acute Respiratory Distress Syndrome: The ARMA Trial
50(2)
25 Timing of Antibiotics in Septic Shock
52(2)
26 Paired Weaning Protocol for Mechanical Ventilation and Sedation: The ABC Trial
54(2)
27 Blood Transfusion for ICU Patients: The TRICC Trial
56(2)
28 Choice of First Vasopressor in Shock: The SOAP II Trial
58(2)
29 Revascularization for Cardiogenic Shock after Myocardial Infarction: The SHOCK Trial
60(2)
30 Early Goal-Directed Therapy in Sepsis
62(2)
31 Prone Positioning in Severe ARDS: The PROSEVA Trial
64(4)
SECTION 3 ENDOCRINOLOGY
Joshua M. Liao
32 ACE Inhibitors for Diabetic Nephropathy
68(2)
33 Bisphosphonates and Fracture Risk: The FIT Trial
70(2)
34 Insulin Therapy and Diabetes Complications: The DCCT Trial
72(2)
35 Hormone Replacement Therapy in Postmenopausal Women: The Women's Health Initiative (WHI) Trial
74(2)
36 Lifestyle Intervention and Metformin in Diabetes: The DPP Study
76(4)
SECTION 4 GASTROENTEROLOGY
Zahir Kanjee
37 Antibiotics in Variceal GI Bleeding
80(2)
38 Transfusion in UGIB
82(2)
39 PPI Before Endoscopy in UGIB
84(2)
40 Albumin in SBP
86(2)
41 10-Year Interval for Screening Colonoscopy
88(2)
42 SAAG in the Diagnosis of Ascites
90(2)
43 Rifaximin in Hepatic Encephalopathy
92(2)
44 "Top-Down" Therapy for Crohn Disease
94(4)
SECTION 5 HEMATOLOGY
Luis Ticona
45 Plasma Exchange in Thrombotic Thrombocytopenic Purpura
98(2)
46 Natural History and Prognosis of MGUS
100(2)
47 The JAK2 Mutation in Myeloproliferative Neoplasms
102(2)
48 Imatinib for CML
104(2)
49 R-CHOP for Diffuse Large B-Cell Lymphoma: The GELA Trial
106(2)
50 HiDAC as Consolidation Therapy for AML
108(2)
51 ATRA Versus Chemotherapy for Acute Promyelocytic Leukemia
110(2)
52 Bortezomib in Relapsed Multiple Myeloma: The APEX Trial
112(2)
53 Optimal Therapy after First Complete Remission in AML
114(2)
54 Genotype for Risk Stratification in Acute Myeloid Leukemia
116(4)
SECTION 6 INFECTIOUS DISEASES
Zahir Kanjee
55 ART for Early Asymptomatic HIV: The START Study
120(2)
56 Direct Acting Antivirals for HCV: The NEUTRINO and FISSION Trials
122(2)
57 Antibiotic Monotherapy for Febrile Neutropenia
124(2)
58 HIV Pre-exposure Chemoprophylaxis: The iPrEx Study
126(2)
59 Oral Vancomycin for Severe C. difficile Infections
128(2)
60 SMX-TMP for PCP Prophylaxis in AIDS
130(2)
61 Combination ART for HIV
132(2)
62 Early ART to Prevent HIV Transmission
134(2)
63 Timing of ART with Acute Ols in HIV
136(2)
64 Oseltamivir for Influenza
138(4)
SECTION 7 NEPHROLOGY
Luis Ticona
65 Intensity of Renal Replacement Therapy in the ICU
142(2)
66 ACE Inhibitors in Chronic Nondiabetic Nephropathy: The REIN Trial
144(2)
67 The MDRD Equation to Estimate GFR
146(2)
68 High-Dose and High-Flux Membrane Use in Hemodialysis: The HEMO Study
148(2)
69 Use of EPO in CKD: The CHOIR Trial
150(2)
70 Renal Transplant Induction Regimen
152(4)
SECTION 8 ONCOLOGY
Luis Ticona
71 Prostatectomy Versus Watchful Waiting for Low-Risk Prostate Cancer: The SPCG-4 Trial
156(2)
72 Low-Dose CT for Lung Cancer Screening: The NLST
158(2)
73 Oxaliplatin as Adjuvant Therapy in Colon Cancer: The MOSAIC Trial
160(2)
74 EGFR Inhibition in Non--Small-Cell Lung Cancer: The IPASS Trial
162(2)
75 HER2-Targeted Therapy in Breast Cancer
164(2)
76 Polypectomy to Prevent Colorectal Cancer: The National Polyp Study
166(2)
77 Prevention of Recurrent VTE with LMWH in Patients with Cancer: The CLOT Trial
168(2)
78 Breast-Conserving Surgery for Early Breast Cancer
170(2)
79 Bevacizumab in Metastatic Colorectal Cancer Treatment
172(2)
80 Aromatase Inhibitors in Early Breast Cancer
174(4)
SECTION 9 PULMONOLOGY
Zahir Kanjee
Joshua M. Liao
81 The Wells Score for Pulmonary Embolism
178(2)
82 Vena Caval Filters: The PREPIC Trial
180(2)
83 Thrombolysis in Acute Pulmonary Embolism
182(2)
84 Combination Long-Acting Beta Agonist and Inhaled Corticosteroid in COPD: The TORCH Trial
184(2)
85 Dabigatran for the Treatment of Venous Thromboembolism: The RE-COVER Trial
186(2)
86 Noninvasive Ventilation for COPD Exacerbations
188(2)
87 LMWH for VTE Prophylaxis: The MEDENOX Trial
190(2)
88 Light's Criteria for Pleural Effusions
192(2)
89 Long-Acting Muscarinic Therapy in COPD
194(2)
90 Inhaled Corticosteroids in COPD
196(2)
91 Glucocorticoids for COPD Exacerbations
198(2)
92 Dual Therapy in Asthma: The FACET Study
200(2)
93 Targeting Molecular Defects in Cystic Fibrosis
202(2)
94 Pirfenidone in IPF: The ASCEND Trial
204(2)
95 Antibiotics in COPD Exacerbations
206(4)
SECTION 10 RHEUMATOLOGY
Joshua M. Liao
96 Anti-TNFα Therapy in Rheumatoid Arthritis
210(2)
97 Treatment of ANCA-Associated Vasculitis: The RAVE Trial
212(2)
98 Hydroxychloroquine in SLE
214(2)
99 Treatment Strategies in RA: The BeSt Study
216(2)
100 Induction Treatment for Lupus Nephritis: The ALMS Trial
218(3)
Index 221